Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:VBLT

Vascular Biogenics (VBLT) Stock Price, News & Analysis

Vascular Biogenics logo

About Vascular Biogenics Stock (NASDAQ:VBLT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.16
$5.46
52-Week Range
N/A
Volume
161,505 shs
Average Volume
2.19 million shs
Market Capitalization
$423.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Receive VBLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vascular Biogenics and its competitors with MarketBeat's FREE daily newsletter.

VBLT Stock News Headlines

Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discovered a new form of power—what some are calling “Helios” technology. It’s not solar, wind, or even nuclear fission. In fact, it could yield more energy than oil, gas, and coal combined—without harmful byproducts. This obscure company could be at the center of the next trillion-dollar energy revolution.
Vascular Biogenics Rises on Presentation Hype
See More Headlines

VBLT Stock Analysis - Frequently Asked Questions

Vascular Biogenics Ltd. (NASDAQ:VBLT) posted its quarterly earnings results on Monday, November, 15th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. The biopharmaceutical company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.20 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vascular Biogenics investors own include T2 Biosystems (TTOO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), OPKO Health (OPK), VBI Vaccines (VBIV), TherapeuticsMD (TXMD) and Vaxart (VXRT).

Company Calendar

Last Earnings
11/15/2021
Today
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:VBLT
Previous Symbol
NASDAQ:VBLX
Employees
7
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-32,300,000.00
Pretax Margin
-3,317.05%

Debt

Sales & Book Value

Annual Sales
$660,000.00
Price / Cash Flow
N/A
Book Value
$0.32 per share
Price / Book
N/A

Miscellaneous

Free Float
72,881,000
Market Cap
$423.91 million
Optionable
Optionable
Beta
0.77

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:VBLT) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners